BioInformatics and Science Advisory Board will review twenty recent market studies on topics ranging from cell biology to pharmacogenomics at the Mid-Atlantic Bio/Med conference in Baltimore
BioInformatics's director of market research, Robin Rothrock, and the Science Advisory Board's director of scientific and medical communications, Tamara Zemlo, will present an overview of twenty recent market studies on topics ranging from cell biology to pharmacogenomics on 4 December at the Mid-Atlantic Bio/Med conference in Baltimore, USA.
Their presentation will follow influential keynote speakers that include Mark McClellan, commissioner of the FDA, Steven Paul, president of Lilly Research Laboratories, and William Haseltine, chairman and CEO, Human Genome Sciences.
"Because of the vital role that our clients play in creating the tools and technologies that drive life science research, our presentation at the Mid-Atlantic Bio/Med conference will help elevate the visibility of the important tools segment of the biotechnology industry," says Bill Kelly, president of BioInformatics.
In their presentation, 'Enabling discovery: the view from the lab bench', Rothrock and Zemlo will showcase the experiences and opinions of thousands of biomedical scientists surveyed by BioInformatics over the last 18 months and provide a Consumer Reports-style look at the companies, instrumentation and consumables that enable cutting-edge research in pharmaceutical, biotechnology and government labs.
Their presentation will enable chief scientific officers, R and D directors, laboratory managers and other attendees to benchmark their own R and D against the technology preferences of researchers in the areas of cell biology, drug discovery, genetics, microbiology, molecular biology, pharmacogenomics and proteomics.
Other topics to be addressed at the conference include bioterrorism, business development, business practicum, clinical testing/trials, drug development, discovery, informatics, policy and the investment community.
With an anticipated attendance of more than 2000 individuals, this conference offers life science companies an opportunity to promote themselves to scientists and researchers in the discovery process, bio and pharma executives in the development process, clinical and medical specialists in the proving process, and other key stakeholders including investors, venture capitalists and service providers.
